Skip to main content
Top
Published in: Annals of Hematology 11/2023

Open Access 10-08-2023 | Hemophagocytic Lymphohistiocytosis | Original Article

A novel prognosis-prediction model based on coagulation indicators in secondary hemophagocytic lymphohistiocytosis

Authors: Shixuan Wang, Kebing Lv, Yulan Zhou, Xiaoye Cheng, Zhiwei Chen, Huimin Shen, Fei Li

Published in: Annals of Hematology | Issue 11/2023

Login to get access

Abstract   

Secondary hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease. In the present retrospective study, we aimed to investigate coagulation disorders and their outcome implications in patients with secondary HLH. We evaluated clinical characteristics and the relationship between coagulation indices and prognosis in HLH patients (n = 141). The information, including clinical symptoms, laboratory indicators, and coagulation indices, was evaluated. Coagulation disorders and bleeding events occurred in 95 (67.4%) and 60 (42.6%) patients, respectively. A coagulation index analysis primarily showed elevated levels of D-Dimer, the international standardized ratio (INR), prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT), while the prothrombin activity, fibrinogen levels, and platelet levels were significantly decreased. Dominant disseminated intravascular coagulation (DIC) occurred in 76 patients (53.9%). Patients with lymphoma-associated hemophagocytic syndrome (LAHS) frequently exhibited apparent coagulation disorders. Multivariate analysis revealed that age ≥ 29.5 years, bleeding events, APTT ≥ 47.3 s, fibrinogen ≤ 1.68 g/L, and absolute neutrophil counts (ANC) of ≤ 1.21 × 109/L were independent prognostic factors. We thereby devised a prognostic scoring system and stratified patients into low-risk (0–2 points), intermediate-risk (3–4 points), and high-risk (5–7 points) groups, and the 1-year overall survival rates in the above-mentioned groups were 66.40%, 40.00%, and 2.30%, respectively (P < 0.0001). In conclusion, coagulation dysfunctions and bleeding tendencies were common characteristics in HLH patients. We constructed a novel prognostic score model based on APTT, fibrinogen level, ANC, age, and bleeding events, which had superior prognostic value compared with these markers alone.
Appendix
Available only for authorised users
Literature
1.
go back to reference Chandrakasan S, Filipovich AH (2013) Hemophagocytic lymphohistiocytosis: Advances in pathophysiology, diagnosis, and treatment. J Pediatr 163:1253–1259CrossRefPubMed Chandrakasan S, Filipovich AH (2013) Hemophagocytic lymphohistiocytosis: Advances in pathophysiology, diagnosis, and treatment. J Pediatr 163:1253–1259CrossRefPubMed
2.
go back to reference Larroche C (2012) Hemophagocytic lymphohistiocytosis in adults: Diagnosis and treatment. Joint Bone Spine 79:356–361CrossRefPubMed Larroche C (2012) Hemophagocytic lymphohistiocytosis in adults: Diagnosis and treatment. Joint Bone Spine 79:356–361CrossRefPubMed
3.
go back to reference Wegehaupt O, Wustrau K, Lehmberg K, Ehl S (2020) Cell versus cytokine - directed therapies for hemophagocytic lymphohistiocytosis (HLH) in inborn errors of immunity. Front Immunol 11:808CrossRefPubMedPubMedCentral Wegehaupt O, Wustrau K, Lehmberg K, Ehl S (2020) Cell versus cytokine - directed therapies for hemophagocytic lymphohistiocytosis (HLH) in inborn errors of immunity. Front Immunol 11:808CrossRefPubMedPubMedCentral
4.
go back to reference Allen CE, Mcclain KL (2015) Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematol Am Soc Hematol Educ Program 2015:177–182CrossRef Allen CE, Mcclain KL (2015) Pathophysiology and epidemiology of hemophagocytic lymphohistiocytosis. Hematol Am Soc Hematol Educ Program 2015:177–182CrossRef
5.
go back to reference Valade S, Mariotte E, Azoulay E (2020) Coagulation disorders in hemophagocytic lymphohistiocytosis/macrophage activation syndrome. Crit Care Clin 36:415–426CrossRefPubMed Valade S, Mariotte E, Azoulay E (2020) Coagulation disorders in hemophagocytic lymphohistiocytosis/macrophage activation syndrome. Crit Care Clin 36:415–426CrossRefPubMed
6.
go back to reference Li F, Yang Y, Jin F, Dehoedt C, Rao J, Zhou Y et al (2015) Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: A retrospective study of increasing awareness of a disease from a single-center in China. Orphanet J Rare Dis 10:20CrossRefPubMedPubMedCentral Li F, Yang Y, Jin F, Dehoedt C, Rao J, Zhou Y et al (2015) Clinical characteristics and prognostic factors of adult hemophagocytic syndrome patients: A retrospective study of increasing awareness of a disease from a single-center in China. Orphanet J Rare Dis 10:20CrossRefPubMedPubMedCentral
7.
go back to reference Li J, Wang Q, Zheng W, Ma J, Zhang W, Wang W et al (2014) Hemophagocytic lymphohistiocytosis: Clinical analysis of 103 adult patients. Medicine (Baltimore) 93:100–105CrossRefPubMed Li J, Wang Q, Zheng W, Ma J, Zhang W, Wang W et al (2014) Hemophagocytic lymphohistiocytosis: Clinical analysis of 103 adult patients. Medicine (Baltimore) 93:100–105CrossRefPubMed
8.
go back to reference Pan H, Huo Y, Sun L (2019) Comparison between clinical features and prognosis of malignancy- and non-malignancy-associated pediatric hemophagocytic lymphohistiocytosis. Bmc Pediatr 19:468CrossRefPubMedPubMedCentral Pan H, Huo Y, Sun L (2019) Comparison between clinical features and prognosis of malignancy- and non-malignancy-associated pediatric hemophagocytic lymphohistiocytosis. Bmc Pediatr 19:468CrossRefPubMedPubMedCentral
9.
go back to reference Kaya Z, Bay A, Albayrak M, Kocak U, Yenicesu I, Gursel T (2015) Prognostic factors and long-term outcome in 52 Turkish children with hemophagocytic lymphohistiocytosis. Pediatr Crit Care Med 16:e165–e173CrossRefPubMed Kaya Z, Bay A, Albayrak M, Kocak U, Yenicesu I, Gursel T (2015) Prognostic factors and long-term outcome in 52 Turkish children with hemophagocytic lymphohistiocytosis. Pediatr Crit Care Med 16:e165–e173CrossRefPubMed
10.
go back to reference Valade S, Joly BS, Veyradier A, Fadlallah J, Zafrani L, Lemiale V et al (2021) Coagulation disorders in patients with severe hemophagocytic lymphohistiocytosis. PLoS ONE 16:e251216CrossRef Valade S, Joly BS, Veyradier A, Fadlallah J, Zafrani L, Lemiale V et al (2021) Coagulation disorders in patients with severe hemophagocytic lymphohistiocytosis. PLoS ONE 16:e251216CrossRef
11.
go back to reference Henter J, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S et al (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131CrossRefPubMed Henter J, Horne A, Aricó M, Egeler RM, Filipovich AH, Imashuku S et al (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48:124–131CrossRefPubMed
12.
go back to reference Valade S, Azoulay E, Galicier L, Boutboul D, Zafrani L, Stepanian A et al (2015) Coagulation disorders and bleedings in critically ill patients with hemophagocytic lymphohistiocytosis. Medicine (Baltimore) 94:e1692CrossRefPubMed Valade S, Azoulay E, Galicier L, Boutboul D, Zafrani L, Stepanian A et al (2015) Coagulation disorders and bleedings in critically ill patients with hemophagocytic lymphohistiocytosis. Medicine (Baltimore) 94:e1692CrossRefPubMed
13.
go back to reference Jin ZL, Wang YN, Wang Z (2017) Clinical analysis of patients with hemophagocytic lymphohistiocytosis complicated with gastrointestinal bleeding. Zhonghua Xue Ye Xue Za Zhi 38:853–857PubMed Jin ZL, Wang YN, Wang Z (2017) Clinical analysis of patients with hemophagocytic lymphohistiocytosis complicated with gastrointestinal bleeding. Zhonghua Xue Ye Xue Za Zhi 38:853–857PubMed
14.
15.
go back to reference Merrill SA, Naik R, Streiff MB, Shanbhag S, Lanzkron S, Braunstein EM et al (2018) A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. Medicine 97:e11579CrossRefPubMedPubMedCentral Merrill SA, Naik R, Streiff MB, Shanbhag S, Lanzkron S, Braunstein EM et al (2018) A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis. Medicine 97:e11579CrossRefPubMedPubMedCentral
16.
go back to reference Yang SL, Xu XJ, Tang YM, Song H, Xu WQ, Zhao FY et al (2016) Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis. Cytokine 85:14–17CrossRefPubMed Yang SL, Xu XJ, Tang YM, Song H, Xu WQ, Zhao FY et al (2016) Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis. Cytokine 85:14–17CrossRefPubMed
17.
go back to reference Janka GE (2007) Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 166:95–109CrossRefPubMed Janka GE (2007) Familial and acquired hemophagocytic lymphohistiocytosis. Eur J Pediatr 166:95–109CrossRefPubMed
18.
go back to reference Saito K, Hirokawa M, Inaba K, Fukaya H, Kawabata Y, Komatsuda A et al (2006) Phagocytosis of codeveloping megakaryocytic progenitors by dendritic cells in culture with thrombopoietin and tumor necrosis factor-alpha and its possible role in hemophagocytic syndrome. Blood 107:1366–1374CrossRefPubMed Saito K, Hirokawa M, Inaba K, Fukaya H, Kawabata Y, Komatsuda A et al (2006) Phagocytosis of codeveloping megakaryocytic progenitors by dendritic cells in culture with thrombopoietin and tumor necrosis factor-alpha and its possible role in hemophagocytic syndrome. Blood 107:1366–1374CrossRefPubMed
19.
go back to reference Madkaikar M, Shabrish S, Desai M (2016) Current updates on classification, diagnosis and treatment of hemophagocytic lymphohistiocytosis (HLH). Indian J Pediatr 83:434–443CrossRefPubMed Madkaikar M, Shabrish S, Desai M (2016) Current updates on classification, diagnosis and treatment of hemophagocytic lymphohistiocytosis (HLH). Indian J Pediatr 83:434–443CrossRefPubMed
21.
go back to reference Tang WP, Zhong N, Chen ZW, Kong FC, Wei YL, Li F (2019) Clinical characteristics of liver dysfunction in patients with hemophagocytic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi 27:1297–1304PubMed Tang WP, Zhong N, Chen ZW, Kong FC, Wei YL, Li F (2019) Clinical characteristics of liver dysfunction in patients with hemophagocytic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi 27:1297–1304PubMed
22.
go back to reference Zhao Y, Lu D, Ma S, Li L, Zhu J, Zhou D et al (2019) Risk factors of early death in adult patients with secondary hemophagocytic lymphohistiocytosis: A single-institution study of 171 Chinese patients. Hematology 24:606–612CrossRefPubMed Zhao Y, Lu D, Ma S, Li L, Zhu J, Zhou D et al (2019) Risk factors of early death in adult patients with secondary hemophagocytic lymphohistiocytosis: A single-institution study of 171 Chinese patients. Hematology 24:606–612CrossRefPubMed
23.
go back to reference Li X, Yan H, Zhang X, Huang J, Xiang ST, Yao Z et al (2020) Clinical profiles and risk factors of 7-day and 30-day mortality among 160 pediatric patients with hemophagocytic lymphohistiocytosis. Orphanet J Rare Dis 15:229CrossRefPubMedPubMedCentral Li X, Yan H, Zhang X, Huang J, Xiang ST, Yao Z et al (2020) Clinical profiles and risk factors of 7-day and 30-day mortality among 160 pediatric patients with hemophagocytic lymphohistiocytosis. Orphanet J Rare Dis 15:229CrossRefPubMedPubMedCentral
24.
go back to reference Yin G, Man C, Huang J, Liao S, Gao X, Tian T et al (2020) The prognostic role of plasma fibrinogen in adult secondary hemophagocytic lymphohistiocytosis. Orphanet J Rare Dis 15:332CrossRefPubMedPubMedCentral Yin G, Man C, Huang J, Liao S, Gao X, Tian T et al (2020) The prognostic role of plasma fibrinogen in adult secondary hemophagocytic lymphohistiocytosis. Orphanet J Rare Dis 15:332CrossRefPubMedPubMedCentral
Metadata
Title
A novel prognosis-prediction model based on coagulation indicators in secondary hemophagocytic lymphohistiocytosis
Authors
Shixuan Wang
Kebing Lv
Yulan Zhou
Xiaoye Cheng
Zhiwei Chen
Huimin Shen
Fei Li
Publication date
10-08-2023
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 11/2023
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-023-05398-w

Other articles of this Issue 11/2023

Annals of Hematology 11/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine